Insurance coverage · 2026 formulary
Does UnitedHealthcare cover Wegovy in 2026?
Short answer: yes on most commercial UHC plans, as a Tier 3 or Tier 4 drug through the OptumRx pharmacy benefit, with prior authorization required. But ~30% of self-funded employer plans (ERISA) carry an explicit weight-loss-drug exclusion that overrides the formulary. Here is exactly what your plan needs to say, what the PA criteria are, and what to do if denied.
Prior authorization criteria
UnitedHealthcare's standard 2026 Wegovy PA form asks for:
- BMI documentation: ≥30 kg/m² alone, or ≥27 kg/m² plus at least one weight-related condition. Height + weight must be from within the last 12 months.
- Qualifying comorbidity: type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, osteoarthritis. One comorbidity is enough at the ≥27 BMI cutoff.
- Lifestyle-intervention attempt: some UHC plans require documented 6-month diet-and-exercise attempt before approval; others skip this. Check your plan-specific PA form.
- Contraindication attestation: prescriber confirms no personal or family history of medullary thyroid carcinoma or MEN 2.
Turnaround: 7-14 days for standard review; 72 hours for expedited (urgent) review. Peer-to-peer review is available if the initial submission is denied — your prescriber can request it directly.
Primary sources — verify against your plan
- UnitedHealthcare Prescription Drug List (PDL) directory — find your plan's exact 2026 formulary PDF
- OptumRx pharmacy benefits (PBM) — Wegovy PA form + coverage lookup tools
- UHC member portal (myuhc.com) — check your plan's specific Wegovy status
Ready to file the PA?
Two ways to move on Wegovy right now
Self-service
Generate a UHC medical-necessity letter
Pre-filled with the exact BMI + comorbidity + step-therapy language UHC's PA form asks for. Bring it to your prescriber to sign.
Delegated
Telehealth providers that handle PA
Compare telehealth clinics that submit PAs on your behalf. Editorially ranked; we earn commission on referrals.
Cost with UnitedHealthcare
| Path | Monthly out-of-pocket | Notes |
|---|---|---|
| UHC + PA approved + savings card | $0-25 | Novo Nordisk WeGoTogether card, up to 12 months |
| UHC + PA approved, no savings card | $25-100 | Standard Tier 3 or 4 copay |
| UHC + PA denied (paying UHC negotiated rate) | $500-700 | Rare — usually you switch to cash |
| Plan excludes weight-loss drugs | $149-499 | Best cash path via telehealth (oral Wegovy $149-299/mo, Novo direct $499/mo) |
| List price (no plan, no coupon) | $1,638 | Almost no one pays this |
If your UHC plan excludes weight-loss drugs
The formulary is what OptumRx approves at the corporate level. The benefit is what your specific plan sponsor (employer) buys. About 30% of large-employer self-funded plans still explicitly exclude weight-loss drugs — this is common in manufacturing, retail, and hospitality benefit packages. If yours does, the appeal path through UHC will not work — you have to change the plan sponsor's decision, or switch to cash.
Cheapest cash paths in 2026
- Oral Wegovy via Hims: $149-299/month self-pay, same 25 mg semaglutide molecule as the injection.
- Novo Nordisk direct (injection): $499/month fixed price, no insurance, via the WeGoTogether program.
- Telehealth aggregators: Ro, Sequence, Found bundle Wegovy at $250-500/month self-pay with membership fee waived.
Affiliate disclosure: Glpverdict earns commission on referrals via partner links. Editorial ranking is independent.
If you got denied
- 1. Read the denial letter carefully. UHC must state the specific PA criterion you missed. Common reasons: BMI documentation gap, missing comorbidity code, no lifestyle-intervention record.
- 2. Get your prescriber to submit a letter of medical necessity. Address the specific criterion in the denial letter. Our appeal letter generator pre-fills the standard GLP-1 denial language.
- 3. Request peer-to-peer review. Your prescriber calls a UHC medical director directly. Approval rate on peer-to-peer is much higher than paper appeals for BMI ≥30 cases.
- 4. External review through your state DOI. Free, independent, binding. State Departments of Insurance overturn ~40-50% of insurer denials on GLP-1 medical-necessity appeals per 2024-2025 KFF data.
This page describes standard UHC + OptumRx 2026 policies. Your specific plan may differ — verify by calling the number on the back of your card or checking the “My Coverage” tool in the UHC member portal. Not medical or benefits advice.
Frequently asked
Does UnitedHealthcare cover Wegovy in 2026?
Yes on most commercial UHC plans — Wegovy is listed on the OptumRx 2026 Premium Formulary as a Tier 3 or Tier 4 weight-management drug with prior authorization required. But roughly 30% of self-funded employer plans (ERISA) carry an explicit weight-loss-drug exclusion that overrides the formulary. Verify your specific plan via the number on the back of your UHC card or the "check my coverage" tool in the UHC member portal.
What are UnitedHealthcare's prior authorization criteria for Wegovy?
The standard 2026 criteria are: (1) BMI ≥30, OR BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), (2) documented 6-month lifestyle-intervention attempt on some plans (not all), (3) prescriber attestation that non-drug options were tried. Approval typically comes in 7-14 days; peer-to-peer review is available if denied.
How much does Wegovy cost with UnitedHealthcare?
With PA approved and no exclusion: commercial copay typically $25-100/month depending on tier. Layer the Novo Nordisk WeGoTogether savings card on top and eligible commercial patients (not Medicare/Medicaid) can pay as little as $0-25/month for up to 12 months. Without coverage: UHC-negotiated cash rate is roughly $500-700/month vs the $1,638 list price.
What if my UnitedHealthcare plan does not cover Wegovy?
Three paths: (1) formal appeal — file within 60 days of the denial letter, include your prescriber's letter of medical necessity, and request peer-to-peer review; (2) self-pay via Novo Nordisk savings card ($499/month direct-to-patient program) or a telehealth provider offering oral Wegovy at $149-299/month; (3) if your employer chose the exclusion, ask HR about upcoming plan-year changes — some large employers restored weight-loss coverage in 2026 under pressure.
Does UnitedHealthcare Medicare Advantage cover Wegovy?
For type 2 diabetes: yes (via the diabetes indication). For weight loss alone: no — Medicare Part D excludes weight-loss drugs by statute (1993 Social Security Act §1860D-2). The 2026 Medicare GLP-1 Bridge program at $50/month applies to Wegovy for cardiovascular-outcome eligible patients with established heart disease — check separately if you qualify.
Does UnitedHealthcare cover Zepbound, Mounjaro, or Ozempic?
Zepbound: same weight-management PA path as Wegovy. Mounjaro + Ozempic: covered on-label for type 2 diabetes with standard tier placement; off-label for weight loss is typically denied.
Can I appeal a UnitedHealthcare Wegovy denial?
Yes. First-level internal appeal within 60 days of the denial letter, decision within 30 days (72 hours if urgent). If denied again, second-level internal appeal, then external independent review through your state's DOI. Our appeal letter generator at /tools/insurance-appeal-letter pre-fills the required medical-necessity language for GLP-1 denials.
Last verified July 11, 2026. Formulary changes quarterly — check the OptumRx PDL for the definitive current status.